NCT07287098 2026-03-16
preEMBER
Eli Lilly and Company
Phase 2 Not yet recruiting
Clinical Trials
15 trialsNCT03056755 2026-01-13
BYLieve
Novartis
Phase 2 Completed
NCT03671330 2025-10-31
Efficacy and Safety of Ribociclib in Pre- and Postmenopausal Chinese Women With HR Positive, HER2-negative, Advanced Breast Cancer.
Novartis
Phase 2 Completed
NCT05607004 2025-10-30
EVANGELINE
Atossa Therapeutics, Inc.
Phase 2 Recruiting
NCT03839823 2024-10-09
RIGHT Choice
Novartis
Phase 2 Completed
NCT04862143 2024-06-20
TELEPIK
Novartis
Phase 2 Terminated
NCT03272477 2024-04-17
TP-II
Palleos Healthcare GmbH
Phase 2 Completed
NCT01252693 2021-10-05
International,Multi-Center,Open Label,Randomized Study Assessing the Safety and Efficacy of a Monthly Dosing Regimen of Ozarelix Versus Goserelin Depot in Men With Prostate Cancer
Spectrum Pharmaceuticals, Inc
Phase 2 Completed
NCT01790126 2020-03-11
The Role of Highly Selective Androgen Receptor (AR) Targeted Therapy in Men With Biochemically Relapsed Hormone Sensitive Prostate Cancer
Aragon Pharmaceuticals, Inc.
Phase 2 Completed
NCT01496131 2018-03-09
Tecemotide (L-BLP25) in Prostate Cancer
EMD Serono
Phase 2 Completed
NCT02107391 2017-05-24
Phase II Study of DCVAC/PCa Added to Hormone Therapy for Men With Metastatic Prostate Cancer
Sotio Biotech Inc.
Phase 2 Completed
NCT01088529 2014-05-15
Neo-adjuvant Abiraterone + Luteinizing Hormone-Releasing Hormone (LHRH) Versus LHRH in Prostate Cancer
Cougar Biotechnology, Inc.
Phase 2 Completed
NCT00322348 2011-01-24
Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women
AstraZeneca
Phase 2 Completed
NCT00235937 2011-01-21
Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex
AstraZeneca
Phase 2 Completed
NCT00303524 2009-12-23
Comparative Study of Oestradiol Suppression: Zoladex 10.8mg/3 Month vs. 3.6mg/Month in ER +ve EBC Pre-menopausal Patients
AstraZeneca
Phase 2 Completed